Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TCGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Conflict of Interest (new) — Sponsor and directors have financial incentives that may conflict with public shareholders' interests.
- Low Price (new) — Founder shares were acquired at a nominal price, creating a misalignment of incentives.
TCGX, a blank check company, files for $75M IPO at $10.00 per share to fund a healthcare acquisition
Filed July 20, 2026 · ~2 min read
Key Changes
-
high
TCGX is offering 7.5 million Class A ordinary shares at $10.00 per share, with an over-allotment option for up to 8.625 million shares.
The Offering verify on EDGAR → -
high
The company will deposit $75 million (or $86.25 million with over-allotment) into a trust account, representing 100% of public offering proceeds.
Use of Proceeds verify on EDGAR → -
high
Net proceeds to the company are $77.5 million, including $5 million from a private placement of 500,000 shares at $10.00 per share to the sponsor and underwriters.
-
high
The sponsor acquired 2,156,250 founder shares for $25,000, or about $0.0116 per share, representing 20% of outstanding shares after the offering.
Dilution verify on EDGAR → -
medium
The company has not selected a business combination target and has no operations or revenue; it intends to focus on healthcare, life sciences, and medical technology.
-
high
The auditor's report includes an explanatory paragraph relating to going concern, indicating substantial doubt about the company's ability to continue as a going concern.
Experts view on EDGAR →
Summary
TCGX Acquisition Corp. is a newly organized blank check company seeking to raise $75 million in an initial public offering of 7.5 million Class A ordinary shares at $10.00 per share. The company plans to use the proceeds to fund a future business combination, with a focus on healthcare, life sciences, and medical technology.
The offering includes a private placement of 500,000 shares at $10.00 per share to the sponsor and underwriters, raising an additional $5 million. The sponsor acquired founder shares at a nominal cost of about $0.0116 per share, representing 20% of the company after the offering, which creates significant dilution for public investors. Several red flags warrant attention.
The auditor's report includes a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue as a going concern. Additionally, the sponsor and directors have financial incentives that may conflict with public shareholders' interests, as they acquired founder shares at a nominal price and could profit even if the business combination underperforms. The company has not yet identified a target business, and there is no assurance that a suitable acquisition will be completed within the required timeframe. Investors should carefully consider these risks before participating in the offering. The company's lack of operating history, the potential for conflicts of interest, and the going concern warning are significant concerns that may affect the value of the investment.
Section-by-Section Diff
The Offering · The Offering
TCGX is a blank check company offering 7.5M Class A shares at $10.00, with a forward purchase agreement and private placement.
Added in current filing · verify on EDGAR →
7,500,000 Class A ordinary shares (or up to 8,625,000 Class A ordinary shares if the underwriters’ over-allotment option is exercised in full), at $10.00 per share.
The company is offering 7.5 million Class A ordinary shares at $10.00 per share, with an over-allotment option for up to 8.625 million shares. This is the primary offering size and price.
Added in current filing · verify on EDGAR →
Fund III will commit that it will purchase from us a minimum of 2,000,000 forward purchase shares, for $10.00 per share, or a minimum aggregate amount of $20,000,000, in a private placement that will close concurrently with the closing of our initial business combination.
Fund III has committed to purchase at least 2 million forward purchase shares at $10.00 per share, totaling $20 million, concurrent with the initial business combination. This provides additional capital but is subject to investment committee approval.
Added in current filing · verify on EDGAR →
Our sponsor and the underwriters have agreed to purchase an aggregate of 500,000 private placement shares (or up to 522,500 private placement shares if the underwriters’ over-allotment option is exercised in full), at a price of $10.00 per share, for an aggregate purchase price of $5,000,000 (or up to $5,225,000 if the underwriter’s over-allotment option is exercised in full) in a private placement that will close simultaneously with the closing of this offering.
The sponsor and underwriters are purchasing 500,000 private placement shares at $10.00 per share, totaling $5 million, simultaneously with the offering. This is a related-party transaction that provides additional funds to the trust account.
Added in current filing · verify on EDGAR →
$75,000,000, or up to $86,250,000 if the underwriters’ overallotment option is exercised in full ($10.00 per share in either case), will be deposited into a segregated trust account located in the United States with Odyssey Transfer and Trust Company acting as trustee, after deducting $1,500,000 in underwriting discounts and commissions payable upon the closing of this offering (or up to $1,725,000 if the underwriters’ overallotment option is exercised in full) and an aggregate of $3,500,000 to pay fees and expenses in connection with the closing of this offering and for working capital following the closing of this offering.
The trust account will hold $75 million (or up to $86.25 million with over-allotment) at $10.00 per share, after deducting underwriting discounts and expenses. This is the amount available for the initial business combination or redemption.
Added in current filing · verify on EDGAR →
On June 3, 2026, our sponsor paid $25,000, or approximately $0.011594 per share, to cover certain of our offering and formation costs in exchange for 2,156,250 founder shares.
The sponsor acquired 2,156,250 founder shares for $25,000, or about $0.0116 per share, significantly below the $10.00 public offering price. These shares will convert to Class A shares and represent 20% of outstanding shares after the offering, creating substantial dilution for public investors.
Added in current filing · verify on EDGAR →
a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in this offering without our prior consent.
The company caps redemptions at 15% of shares sold in the offering for any shareholder group, which limits the ability of large holders to redeem and could force them to vote against a deal or accept terms. This is a structural feature of the SPAC that affects shareholder liquidity and deal completion.
Added in current filing · verify on EDGAR →
Our sponsor paid a nominal aggregate purchase price of $25,000 for the founder shares, or approximately $0.011594 per share.
The sponsor acquired founder shares at about $0.0116 per share, far below the $10.00 public offering price. This creates a strong incentive for insiders to complete a deal even if it is not in public shareholders' best interests.
Added in current filing · verify on EDGAR →
Repayment of up to $300,000 in loans made to us by our sponsor to cover offering-related and organizational expenses;
The company will repay up to $300,000 in sponsor loans for offering and organizational expenses from funds outside the trust account. This is a direct payment to insiders that reduces cash available for the business combination.
Use of Proceeds · Use of Proceeds
SPAC offering 7.5M units at $10.00; $75M to trust, $2.5M working capital, $1M expenses, $1.5M underwriting.
Added in current filing · verify on EDGAR →
We are offering 7,500,000 Class A ordinary shares at an offering price of $10.00 per share.
The company is offering 7.5 million Class A ordinary shares at $10.00 per share, raising $75 million from public investors before expenses. This is a preliminary offering size and price as stated in the S-1 filing.
Added in current filing · verify on EDGAR →
$75,000,000 ($10.00 per share), or up to $86,250,000 if the underwriters’ over-allotment option is exercised in full ($10.00 per share), will be deposited into a trust account
The company will deposit $75 million (or $86.25 million if the over-allotment option is fully exercised) into a trust account, representing 100% of the public offering proceeds. These funds are restricted and can only be used for a business combination or shareholder redemptions.
Added in current filing · verify on EDGAR →
$2,500,000 for working capital following the closing of this offering
The company will retain $2.5 million outside the trust account for working capital, which is intended to cover operating expenses until a business combination is completed. This amount is fixed and does not increase with the over-allotment option.
Added in current filing · verify on EDGAR →
Underwriting commissions (excluding deferred portion) (4) $ 1,500,000 $ 1,725,000
The underwriters will receive $1.5 million in upfront commissions (or $1.725 million if the over-allotment option is exercised), which is 2% of the gross proceeds. An additional 4% deferred commission of up to $3 million (or $3.45 million) is payable only upon completion of a business combination.
Added in current filing · verify on EDGAR →
we plan to enter into a forward purchase agreement with Fund III, pursuant to which Fund III will commit that it will purchase from us a minimum of 2,000,000 forward purchase shares, for $10.00 per share, or a minimum aggregate amount of $20,000,000
The company plans to enter into a forward purchase agreement with Fund III, which commits to buy at least 2 million shares at $10.00 per share ($20 million) in a private placement concurrent with the business combination. This provides additional capital but is subject to Fund III's investment committee approval.
Dilution · Dilution
SPAC discloses founder share purchase price of ~$0.0116/share, transfer restrictions, and potential dilution for public shareholders.
Added in current filing · verify on EDGAR →
The founder shares were purchased for $25,000, or approximately $0.011594 per share.
The sponsor acquired 2,156,250 Class B ordinary shares for $25,000, implying a per-share cost of about $0.0116. This is far below the $10.00 per share public offering price, meaning the sponsor's shares will be substantially diluted in value relative to public shares if the business combination occurs.
Added in current filing · verify on EDGAR →
The proposed private placement is expected to be $5,000,000, consisting of 500,000 private placement shares purchased at $10.00 per share, with $4,250,000 expected to be purchased by our sponsor and $750,000 expected to be purchased by the underwriter.
The company expects to raise $5.0 million in a private placement at $10.00 per share, with the sponsor buying $4.25 million and the underwriter $0.75 million. These shares are additional equity that will dilute public shareholders and are subject to only a 30-day lock-up.
Added in current filing · verify on EDGAR →
If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares).
The sponsor and initial shareholders will maintain 20% ownership of the company's ordinary shares after the offering, excluding private placement shares. This means public investors will own the remaining 80%, but the founder shares were acquired at a nominal cost, creating significant dilution for public shareholders.
Added in current filing · verify on EDGAR →
The founder shares are not transferable or saleable until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination.
Founder shares are locked up for at least one year after the business combination, with an early release trigger if the stock trades at $12.00 or more for 20 of 30 trading days starting 180 days post-combination. This lock-up may reduce near-term selling pressure but also signals potential future dilution when restrictions lapse.
Added in current filing · verify on EDGAR →
The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination.
Private placement shares purchased by the sponsor and underwriter at $10.00 per share are locked up for only 30 days after the business combination, a much shorter period than the founder shares. This could lead to earlier selling pressure from these holders.
Risk Factors · Risk Factors
SPAC risk factors covering shareholder voting, redemption rights, trust account, and completion window.
Added in current filing · verify on EDGAR →
Our initial shareholders will own 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (assuming our initial shareholders do not purchase any shares in this offering and excluding the private placement shares). After taking into account the private placement shares to be issued to the sponsor, our sponsor will own an aggregate of 2,210,000 ordinary shares, or 22.4% of our issued and outstanding ordinary shares immediately following the completion of this offering assuming the over-allotment option is not exercised, or an aggregate of 2,502,500 ordinary shares, or 22.1% of our issued and outstanding ordinary shares immediately following the completion of this offering, assuming the over-allotment option is exercised in full.
The sponsor and initial shareholders will hold a significant stake (20% excluding private placement shares, 22.4% including them) immediately after the offering. This concentrated ownership gives them substantial influence over the initial business combination vote, even if public shareholders oppose it.
Added in current filing · verify on EDGAR →
we would need 2,562,501, or 34.2%, of the 7,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved by way of ordinary resolution (assuming all outstanding shares are voted and the over-allotment option is not exercised and the parties to the letter agreement do not acquire any public shares).
Because the founder shares and private placement shares are already committed to vote in favor, only 34.2% of public shares need to vote yes for approval if all shares are voted. This lowers the bar for completing a business combination that public shareholders may not support.
Added in current filing · verify on EDGAR →
our public shareholders may receive only $10.00 per public share, or less than $10.00 per public share, on the redemption of their shares.
If the company fails to complete a business combination within the completion window, public shareholders may receive only $10.00 per share or less, not the full amount initially held in trust, due to potential claims, taxes, and dissolution expenses.
Added in current filing · verify on EDGAR →
we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor’s only assets are securities of our company.
The sponsor has agreed to indemnify the company for certain claims that reduce the trust account below $10.00 per share, but the sponsor's only assets are securities of the company and no reserve has been set aside. This means the indemnity may be worthless if the sponsor lacks other funds.
Added in current filing · verify on EDGAR →
In connection with the consummation of this offering, we plan to enter into a forward purchase agreement with Fund III, pursuant to which Fund III will commit that it will purchase from us a minimum of 2,000,000 forward purchase shares, for $10.00 per share, or a minimum aggregate amount of $20,000,000, in a private placement that will close concurrently with the closing of our initial business combination.
The company plans to rely on a forward purchase agreement with Fund III for at least $20 million to fund its initial business combination. If that sale fails to close, the company may lack sufficient funds to complete a deal. This is a company-specific financing risk.
Added in current filing · verify on EDGAR →
In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as converted basis, 20% of the total number of Class A ordinary shares outstanding after such conversion (excluding the private placement shares and forward purchase shares, and after giving effect to any redemptions of Class A ordinary shares by public shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial business combination and any private placement shares issued to our sponsor, officers or directors upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one basis.
Founder shares convert to maintain a 20% ownership stake after the business combination, even if additional shares are issued. This anti-dilution mechanism protects insiders but can significantly dilute public shareholders. The provision is specific to this SPAC's structure.
Added in current filing · verify on EDGAR →
After taking into account the private placement shares to be issued to the sponsor, our sponsor will own an aggregate of 2,210,000 ordinary shares, or 22.4% of our issued and outstanding ordinary shares immediately following the completion of this offering assuming the over-allotment option is not exercised, or an aggregate of 2,502,500 ordinary shares, or 22.1% of our issued and outstanding ordinary shares immediately following the completion of this offering, assuming the over-allotment option is exercised in full.
The sponsor will hold over 22% of the company after the offering, giving it substantial influence over shareholder votes. This concentration of control could disadvantage public shareholders with different interests.
Added in current filing · verify on EDGAR →
The provisions of our amended and restated memorandum and articles of association that relate to our pre-business combination activity (and corresponding provisions of the agreement governing the release of funds from our trust account) may be amended with the approval of holders of not less than two-thirds of our ordinary shares which are represented in person or by proxy and are voted at a general meeting of the company, which is a lower amendment threshold than that of some other special purpose acquisition companies.
The company can amend key pre-business combination provisions with a two-thirds vote, which is lower than many other SPACs. This makes it easier to change terms in ways that may not align with public shareholder interests.
MD&A · Management's Discussion and Analysis
TCGX is a blank check company targeting healthcare, with no operations or revenue, planning a $75M IPO to fund a future acquisition.
Added in current filing · verify on EDGAR →
We are a newly organized blank check company incorporated on May 26, 2026 as an exempted company under the laws of the Cayman Islands for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
The company is a blank check company with no operations or revenue to date. It has not selected any business combination target and has not engaged in substantive discussions with any target. This is a typical SPAC structure, but investors should note the lack of operating history and the speculative nature of the investment.
Added in current filing · verify on EDGAR →
We estimate that the net proceeds from the sale of Class A ordinary shares in this offering and the sale of the private placement shares for an aggregate purchase price of $5,000,000 (or up to $5,225,000 if the underwriters’ over-allotment option is exercised in full), after deducting offering expenses of approximately $1,000,000 and underwriting commissions of $1,500,000 (or up to $1,725,000 if the underwriters’ over-allotment option is exercised in full) (excluding deferred underwriting commissions of $3,000,000, or up to $3,450,000 if the underwriters’ over-allotment option is exercised in full), will be $77,500,000 (or up to $88,750,000 if the underwriters’ over-allotment option is exercised in full).
The company expects net proceeds of $77.5 million (or $88.75 million if over-allotment is exercised) from the offering and private placement. $75 million (or $86.25 million) will be placed in a trust account, and approximately $2.5 million will be held outside the trust for working capital. The trust account includes deferred underwriting commissions of $3 million (or $3.45 million).
Added in current filing · verify on EDGAR →
The issuance of additional shares in connection with a business combination to the owners of the target or other investors, including the forward purchase securities: may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;
The company warns that issuing additional shares for a business combination could significantly dilute investors. The anti-dilution provisions in Class B ordinary shares could cause conversion to Class A shares at a ratio greater than one-to-one, further increasing dilution. This is a common SPAC risk but is important for investors to understand.
Added in current filing · verify on EDGAR →
With funds available for an initial business combination initially in the amount of $72,000,000, after payment of $3,000,000 of deferred underwriting fees, assuming no exercise of the underwriters’ over-allotment option
The company will have $72 million in the trust account for a business combination, after paying deferred underwriting fees. This is the primary capital available for an acquisition.
Added in current filing · verify on EDGAR →
Our initial shareholders currently own an aggregate of 2,156,250 Class B ordinary shares, which we refer to as the founder shares throughout this prospectus. The founder shares were purchased for $25,000, or approximately $0.011594 per share.
Founder shares were acquired at a nominal price of about $0.0116 per share, giving insiders a large ownership stake at minimal cost. This creates significant dilution for public shareholders.
Added in current filing · verify on EDGAR →
Our liquidity needs have been satisfied prior to the completion of this offering through receipt of a $25,000 capital contribution from our sponsor in exchange for the issuance of the founder shares to our sponsor and up to $300,000 in an available loan from our sponsor.
The sponsor contributed $25,000 for founder shares and provided a loan of up to $300,000. The loan is non-interest bearing, unsecured, and due at the earlier of December 31, 2027 or the closing of this offering. It is expected to be repaid from offering proceeds allocated for offering expenses.
Added in current filing · verify on EDGAR →
While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare and healthcare-related industries. In particular, we intend to target companies in the life sciences and medical technology sectors, where our management and TCGX (as defined below) have extensive investment experience.
The company intends to focus on healthcare, life sciences, and medical technology, leveraging the experience of its management team and TCGX. It may also pursue targets in Asia, including China, which introduces additional regulatory and enforcement risks. This focus is a key differentiator for the SPAC.
Added in current filing · verify on EDGAR →
The proposed private placement is expected to be $5,000,000, consisting of 500,000 private placement shares purchased at $10.00 per share, with $4,250,000 expected to be purchased by our sponsor and $750,000 expected to be purchased by the underwriter.
The sponsor and underwriter will purchase private placement shares at $10.00 per share, providing additional capital. This is separate from the public offering and benefits insiders.
Business · Business
TCGX is a blank check company seeking a business combination, with standard SPAC redemption and trust account mechanics.
Added in current filing · verify on EDGAR →
The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a shareholder vote. In either case, our public shareholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed business combination.
The redemption price is initially anticipated to be $10.00 per share, but the actual amount will depend on the trust account balance at the time of redemption. This is a standard SPAC mechanism, but the specific per-share amount is important for investors evaluating the downside protection.
Added in current filing · verify on EDGAR →
$75,000,000 of the net proceeds of this offering and the sale of the private placement shares will be deposited into a trust account located in the United States with Odyssey Transfer and Trust Company acting as trustee.
The company will place $75 million of net proceeds into a trust account, which is the primary source of funds for redemptions. This figure is specific to TCGX and indicates the scale of the offering.
Added in current filing · verify on EDGAR →
We must complete one or more business combinations having an aggregate fair market value of at least 80% of our assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination.
TCGX is required to acquire a target business with a fair market value of at least 80% of the trust account assets. This constraint shapes the type and size of potential acquisition targets.
Added in current filing · verify on EDGAR →
If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated memorandum and articles of association provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares without our prior consent.
Shareholders holding more than 15% of the shares sold in the offering may be restricted from redeeming those excess shares without company consent. This limits the redemption rights of large investors and could affect their exit strategy.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
We currently have two executive officers: Chen Yu, M.D., M.B.A., our Chief Executive Officer and a director, and Craig Skaling, our Chief Financial Officer and a director.
The company is led by two executive officers who are also directors. They are not obligated to devote any specific number of hours to the company, which is typical for a SPAC but relevant for investors assessing management commitment.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify